This is a mobile optimized page that loads fast, if you want to load the real page, click this text.

MVP - Medical Developments International

Jump to new

Joe Blow

Administrator
Staff member
Joined
28 May 2004
Posts
10,893
Reactions
5,389
Medical Developments International Limited (MVP) is a healthcare company in pain relief and respiratory medicine. MDI has a range of products for pain management, asthma, oxygen delivery and veterinary use. The company consists of three major business divisions: Pharmaceutical; Medical Devices, and Veterinary.

http://www.medicaldev.com
 
Wow, not one post for this one which has been in uptrend since June 2010. Broke out again today. I hold.

Cheers
Country Lad



 
Country Lad said:
Wow, not one post for this one which has been in uptrend since June 2010. Broke out again today. I hold.
Click to expand...

Yes a very strong trend indeed. I bought some on open today. The market was slow to react to the positive announcement, but by the afternoon the sell depth is non-existence.

This is a case where we need some sellers to attract the buyers.
 
MVP - Medical Developments Int.

Got in on these guys at 1.14 and 1.38. good future plans as well for growth, have been a nice stock for me so far, would recommend to anyone
 
Re: MVP - Medical Developments Int.

Yacob said:
would recommend to anyone
Click to expand...

Hi Yacob,

Welcome to ASF.

Can you elaborate as to why you would recommend this stock? WHat do you like about it in particular?
 
It's a shame we no longer have Country Lad around anymore with his wonderful Point & Figure charts which I would love to emulate but I know I wasn't born with that talent unfortunately.

However this stick as been going gangbusters. In that since the beginning of the year the price as doubled from $3 to $6. Today's action saw it close up (2%) breaking out of an ascending triangle on increasing volume.

Please remember to do your own research prior to purchasing or selling shares
 
Nice rise today with the deal from China.
I bought some, sweated as they did a raising SPP buut now am comfortably on top as the price takes off.
I think its a long term buy. Government Bureaucracy is its problem. Funny how they can sell to Japan and New Zealand but have to wait for committees and rules etc. in Europe and especially in the USA.
 
A big jump today of 34c to $4.24.
Not sure why, maybe a deal being finalised in the USA?
 
Last edited:
Another big jump. Now $4.83. What is going on?
 
My pick for the month.
Green whistle now entering more markets. Hoping for a deal into the suss US markets which is the only country blocking it despite the many advantages with regard pain management and proven safety. Will require a US partner, the continuing price rise suggests one may be on the horizon.
 
Lower Aussie dollar and lower interest rates mean increased profits in a range of companies but this one may gain the most as manufacturing is in Australia and is expanding overseas.
 
eps increased from 0.41c to 1.61c.

Profit up 326.8% after tax.

Dividend 2c a share.

The rollout is just beginning. Surely 2.8c per share for the following year is reachable. when they get into the USA market, this will further increase earnings.

Cashflow is positive. Bank debt is practically zero.

I'm happy.
 
It's rising again so I am hoping it will continue to do so for the comp.
Hoping to hear some good news re: Penthrox.
 
More good news, good to be in with MundiPharma.

Penthrox® entered in the European Society of Emergency Medicine (“EUSEM”) guidelines as now being recommended and approved as “first-line of treatment”

Medical Developments International Ltd (ASX: MVP) is delighted to announce that Penthrox has been

included in the new EUSEM guidelines for the “Management of acute pain in emergency situations”. These new guidelines are published on the EUSEM website and can be found

at: https://eusem.org/education/guidelines. The Guidelines cover all aspects of acute pain management in emergency situations across Europe.


Inclusion in these guidelines is a pivotal moment for Penthrox which is now a “first-line of treatment” option in both moderate and severe pain.


Clinical study data contained in the InMEDIATE and MEDITA studies is included within the guidelines providing clinical evidence supporting the Penthrox use. The Guidelines were sponsored financially by an educational grant from Mundipharma International Limited who had no editorial input.
 
You must log in or register to reply here.

Similar threads

AEAE - Australian Ethical High Conviction Fund ETF
Replies
2
Views
2K
Garpal Gumnut
IPD - ImpediMed Limited
Replies
15
Views
9K
Dona Ferentes
The Beginner Trader's Manual Guide
Replies
9
Views
20K
commoyo
AJJ - Asian American Medical Group
Replies
16
Views
8K
McLovin
AVH - AVITA Medical, Inc
3 4 5
Replies
86
Views
27K
Dona Ferentes
Menu
Log in
Register
Cookies are required to use this site. You must accept them to continue using the site. Learn more...